Prof. Dr. Zafer Gülbaş is a hematologist-oncologist and founding director of the bone-marrow transplant centre at Anadolu Medical Center — one of the largest such programmes in Turkey. Since 2010 his team has performed more than 3,000 transplants, including autologous, allogeneic (related, unrelated and haploidentical) and stem-cell procedures.
He trained at leading cancer centres including Fred Hutchinson Cancer Research Center (Seattle), MD Anderson and Princess Margaret Hospital (Toronto), and has published over 260 scientific papers with more than 5,000 citations.
Procedures performed
Specialties
Education & training
- DegreeHacettepe University School of Medicine
- DegreeAnadolu University School of Medicine
Professional memberships
- MembershipEuropean Hematology Association (EHA)
- MembershipAmerican Society of Hematology (ASH)
- MembershipEuropean Society for Medical Oncology (ESMO)
Membership reflects participation in a professional body — not an endorsement of this doctor by that organization.
What happens after you send a request
- You send a request through the form — this does not commit you to treatment.
- An XCuro coordinator contacts you to understand what you are looking for.
- You share the relevant medical details and photos for the clinic to review.
- The clinic's medical team assesses suitability and prepares a proposal.
- If you decide to go ahead, you plan the appointment and travel together.
Whether a procedure is suitable for you — and the technique, risks and likely results — can only be confirmed by an individual medical assessment.
About the clinic
JCI-accredited multidisciplinary hospital near Istanbul, affiliated with Johns Hopkins Medicine — a leading centre for oncology and bone-marrow transplantation.
View clinic profilePatient reviews
Reviews coming soon
We're collecting verified patient experiences for Dr. Zafer Gülbaş. Considering treatment? Our team will gladly connect you with past patients.
Research & evidence
12 peer-reviewed sourcesPeer-reviewed studies relevant to the procedures Zafer Gülbaş performs. Compiled from systematic reviews, meta-analyses and clinical research indexed on PubMed.
- Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.
- Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.
- Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.
- Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis.
- Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression.
Compiled from peer-reviewed medical literature indexed on PubMed. This overview is for general education and is not medical advice.